The introduction of imatinib mesylate (Gleevec) has dramatically changed the management and prognostic outlook of patients with chronic myeloid leukemia (CML).
Alfonso Quintás-cardama, MD
Advertisement
Articles by Alfonso Quintás-cardama, MD
Advertisement
Latest Updated Articles
- Management of Patients With Resistant or Refractory Chronic Myelogenous Leukemia
Published: April 15th 2008 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Epcoritamab Combo in R/R Follicular Lymphoma
2
FDA Grants Fast Track Designation to Novel Imaging Agent in Clear Cell RCC
3
Evaluating the EVA1 Membrane Protein as a Target for Glioblastoma Therapy
4
Zanidatamab-Based Regimens Exhibit Improved PFS in Gastroesophageal Cancers
5
